Hims vs Ro for GLP-1 Weight Loss: Side-by-Side Comparison (May 2026)

For most of 2024 and into 2025, comparing Hims and Ro for GLP-1 weight loss meant comparing two compounding telehealth platforms on dosage flexibility, pharmacy quality, and price-per-milligram. That comparison is now obsolete. Both companies pivoted to branded-only in 2025 and early 2026, both route Wegovy through Novo Nordisk’s NovoCare Pharmacy at the same manufacturer-set self-pay price, and both run async-only prescriber models.

The actual decision point in May 2026 is narrower: a roughly $50/month difference in platform fee, Hims’s exclusive access to the oral Wegovy pill, and subtle differences in the support model and clinical positioning. This page walks through each dimension with sourced pricing.

About this comparison: Built from public pricing pages, Novo Nordisk NovoCare partnership announcements, and SEC filings. Hands-on sign-up verification is pending for both platforms; claims are linked to public sources. If you spot an error, email [email protected].

TL;DR verdict

Choose Ro if your priority is the lowest monthly all-in cost for branded injectable Wegovy on a cash-pay telehealth platform. Ro’s platform fee is approximately $50/month lower than Hims’s at steady state; you get the same NovoCare drug at the same price.

Choose Hims if you want the oral Wegovy pill (FDA-approved 1.5 mg and 4 mg tablets), which Ro does not offer as of May 2026. The oral option matters for patients who prefer not to self-inject or who are in a geographic area with injection supply constraints.

Neither beats NovoCare direct if you already have a prescriber. Both platforms are charging a membership fee on top of the NovoCare drug price. A patient who gets a Wegovy prescription from their own primary care doctor and fills through NovoCare pays $349/month — the same drug, $99–$149 less per month.

At-a-glance comparison

Pricing from publicly published rates as of May 2026. Verify current pricing directly with each platform before enrolling — both adjust fees periodically.

Pricing reality

The drug price is the same

The single most important pricing fact about this comparison: for branded Wegovy injectable, Hims and Ro charge the same drug price because they both source through NovoCare. Novo Nordisk sets the NovoCare self-pay price; neither telehealth platform marks it up. That price is $199/month for the 0.25 mg and 0.5 mg starting doses for the first two months, then $349/month at all standard doses thereafter.

For tirzepatide (Zepbound), both platforms route through LillyDirect at Lilly’s published vial prices, which start at approximately $299/month for the 2.5 mg starting dose.

Platform fees are the differentiator

Where Hims and Ro actually diverge on cost is the monthly platform membership fee — the charge for the prescriber relationship, ongoing messaging, and refill management.

At steady state, Ro costs approximately $600 less per year than Hims for the same branded injectable Wegovy. That is the core financial argument for Ro.

Hims oral Wegovy changes the maths for pill-preferrers

Hims’s unique position is the FDA-approved oral Wegovy (semaglutide) pill, launched in conjunction with its March 2026 Novo Nordisk settlement. Introductory pricing for oral Wegovy at Hims has been reported at approximately $149/month for the lower doses, rising to $249/month and above at higher doses. If your prescriber recommends an oral formulation and Ro doesn’t offer one, the comparison shifts and Hims becomes the only branded-oral option in the telehealth channel as of May 2026.

NovoCare direct costs less than either platform

For full context: a patient who already has a prescriber (primary care, endocrinologist, or a standalone low-cost prescriber service) can fill Wegovy through NovoCare directly at $349/month — the same drug, zero platform fee. The combined Hims all-in ($498) and Ro all-in ($448) are both higher than NovoCare direct ($349). The premium you pay at Hims or Ro is for the bundled prescriber relationship. Whether that is worth it depends on whether you would otherwise have no prescriber — see NovoCare enrollment without a telehealth platform.

What each platform offers in 2026

How both became branded-only

Ro made the quieter pivot. When Novo Nordisk announced its NovoCare telehealth partner programme in April 2025 — alongside LifeMD and WeightWatchers Clinic — Ro was one of the three named launch partners (CNBC; STAT News). Ro wound down its compounded semaglutide programme without the legal drama that characterised the Hims timeline.

Hims took the longer route. The Novo–Hims partnership announced in April 2025 was terminated by Novo in June 2025 citing “illegal mass compounding and deceptive marketing.” An FDA warning letter followed in September 2025. Hims launched, then quickly withdrew, a compounded semaglutide pill in February 2026. Novo sued for patent infringement on February 9, 2026. The parties settled on March 9, 2026: Hims agreed to stop marketing compounded GLP-1 products, and Novo agreed to provide access to branded Wegovy and Ozempic at its self-pay prices (Hims press release). As of May 2026, Hims is winding down existing compounded-patient relationships and enrolling new patients exclusively on branded products.

The result: both companies are now selling the same branded drugs through the same NovoCare channel. The compounding history shapes brand perception but not the product on the shelf today.

Sign-up and intake experience

Both platforms use async intake models: you complete an online health questionnaire, a licensed prescriber reviews your responses, and you receive a decision — typically within 24 hours on business days — without a synchronous video call. There are no in-person requirements. Neither platform requires lab work before the initial prescription, though both may recommend labs depending on your medical history.

Hims intake is designed around its broader telehealth ecosystem (hair loss, skin, mental health, ED). The weight-loss intake sits within this multi-condition app. Some public accounts describe the intake as fast and low-friction; others note that the multi-condition framing means the weight-loss pathway isn’t as prominently separated as a dedicated obesity platform.

Ro intake is more focused on metabolic health. Ro Body is a distinct programme rather than one of many categories in a generalist app. Public accounts describe the intake as structured but still entirely async — not a video consultation.

Neither platform requires insurance or runs prior authorisation as part of the core cash-pay intake.

Drug availability

What Hims prescribes (May 2026)

• Wegovy injectable (semaglutide pen) — all doses including 7.2 mg HD formulation; NovoCare self-pay pricing
• Wegovy oral pill (FDA-approved 1.5 mg and 4 mg tablets) — Hims-exclusive in the telehealth channel as of May 2026
• Ozempic (semaglutide) — at NovoCare prices
• Zepbound (tirzepatide) — via LillyDirect

What Ro prescribes (May 2026)

• Wegovy injectable (semaglutide pen) — NovoCare self-pay pricing
• Ozempic (semaglutide) — NovoCare prices
• Zepbound (tirzepatide) — via LillyDirect
• Mounjaro (tirzepatide) — via LillyDirect

The oral Wegovy gap

Hims’s exclusive offer of the FDA-approved oral Wegovy pill is the most concrete drug-access differentiator between the two platforms. Oral semaglutide was approved for chronic weight management in adults by the FDA, offering a needle-free alternative for patients who prefer not to self-inject. Ro has not published oral Wegovy availability as of May 2026.

If you or your prescriber are considering oral semaglutide as the preferred formulation, Hims is currently the only NovoCare-channel telehealth platform offering it.

Mounjaro gap

Ro prescribes Mounjaro (tirzepatide for type 2 diabetes management, off-label for weight) in addition to Zepbound; Hims lists Zepbound specifically. For patients whose prescriber prefers the Mounjaro indication, Ro’s flexibility is relevant.

Support quality

Both platforms operate async-only clinical support — no synchronous video consultations. You communicate with your clinical team via messaging within each app.

Hims support is consistently described in public accounts as functional for routine refill requests and dose titration. The main friction reported involves more complex queries — side-effect management or dose escalation concerns that require nuanced clinical judgment can take 24–48 hours for a substantive response. Hims does include anti-nausea medication (ondansetron) at no additional cost if your prescriber determines it’s appropriate, which reflects an attempt to handle a common early GLP-1 side effect within the platform.

Ro support draws similar characterisations for routine questions. Ro’s metabolic health focus means the clinical team messaging is specifically oriented toward weight-loss management rather than distributed across dozens of health categories. Some public accounts describe faster response times at Ro versus Hims for weight-loss-specific queries, though this varies and is not formally measured in any public data.

What neither platform offers that higher-cost programs do: synchronous video consultations with an obesity medicine specialist, dietitian or nutrition coaching, metabolic lab monitoring as a standard inclusion, or body composition tracking. Both Hims and Ro are prescriber-and-medication platforms; the clinical depth of programs like Form Health, Calibrate, or Knownwell is a different product tier.

Patient experience across public forums (r/Semaglutide, r/Ozempic, r/WeightLoss) shows several recurring themes worth noting:

• Users who switched from Hims to Ro or vice versa most often cite the platform fee difference as the trigger, not dissatisfaction with clinical quality. Once on the same NovoCare drug, the medication experience is identical by definition.
• Complaints about Hims’s support are more frequent in posts from 2025 when the company was navigating its compounding-to-branded transition; early 2026 accounts are more neutral as the product stabilised.
• Ro users on public forums frequently mention the structured, metabolic-focused messaging as a positive, particularly for patients who found the Hims multi-condition app less focused for weight-loss management specifically.
• Both platforms receive criticism for the absence of video consultations — users who want a synchronous relationship consistently describe async-only models as insufficient for managing complex metabolic conditions.

Cancellation comparison

Both platforms are broadly comparable on cancellation: cancel before the billing cycle, no refund on the current period. The key practical point for both: your Wegovy or Ozempic prescription is your medical record and can be transferred to NovoCare directly or any licensed pharmacy after cancellation. You are not locked into the platform to continue your medication — you are locked into the platform for ongoing prescriber support, dose adjustments, and refill authorisation.

Hims prepaid plans carry the greater cancellation risk. If you chose a multi-month prepaid plan to access a lower advertised rate, the no-refund policy means unused months are lost. Monthly billing plans at full price carry less financial risk on exit. Verify the billing structure before enrolling.

Who should choose Hims

Hims is the right choice if:

• You want the oral Wegovy pill (FDA-approved, needle-free). Hims is currently the only branded telehealth platform offering this option, and for patients who prefer not to self-inject, it removes a significant barrier.
• You are already a Hims customer using the platform for hair loss, skin, or another health category and want to consolidate your prescriber relationships in one app.
• You want access to the Wegovy HD 7.2 mg dose tier and want to manage it through the same platform you use for initial titration.
• You are comfortable paying ~$50 more per month for the same injectable drug in exchange for Hims’s specific platform UX and support model.

Hims is not ideal if:

• Your priority is the lowest total monthly cost — Ro is cheaper for the same injectable drug.
• You want video consultations or synchronous access to an obesity specialist.
• You want a dedicated metabolic health coaching layer.

Who should choose Ro

Ro is the right choice if:

• You want the lowest all-in cash-pay cost for branded injectable Wegovy on a telehealth platform. At ~$448/month versus Hims’s ~$498, the difference compounds to roughly $600/year.
• You want a dedicated metabolic health platform rather than a multi-category telehealth service — Ro Body is structured around weight management specifically.
• You want Mounjaro prescribed via tirzepatide (Ro explicitly offers it; Hims lists Zepbound specifically).
• You are coming off a compounding platform and want the lowest-friction branded transition — Ro’s NovoCare integration has been live since April 2025, giving it more operational maturity in the branded channel.

Ro is not ideal if:

• You want the oral Wegovy pill — Ro does not offer it as of May 2026.
• You want the lowest possible cost overall — NovoCare direct at $349/month is cheaper than Ro if you have or can obtain your own prescription.
• Your commercial insurance covers GLP-1s — an insurance-first program (Form Health, Calibrate, WeightWatchers Clinic) will be meaningfully cheaper.

A note on NovoCare direct

Before enrolling in either Hims or Ro, it is worth checking whether you can obtain a Wegovy prescription through your existing healthcare relationship and fill through NovoCare directly. The NovoCare drug price — $349/month at standard doses — is the floor for both platforms; the platform membership fee is paid on top of that price. If your primary care doctor, ob-gyn, or endocrinologist will prescribe Wegovy, NovoCare direct at $349/month costs $99–$149 less per month than Hims or Ro.

See NovoCare enrollment without a telehealth platform and Wegovy without insurance for detail on accessing the manufacturer price directly.

Full provider context

This comparison covers two platforms. For the full landscape — manufacturer-direct channels, insurance-first programs, and the remaining compounding providers — see the provider comparison page.

For deeper reviews of each platform independently, see Hims weight loss review and Ro Body review.

This comparison is built from public sources — published pricing pages, press releases, Novo Nordisk partnership announcements, and SEC filings. It is editorial analysis, not clinical advice. We have not yet completed a hands-on sign-up at either platform; a hands-on update will be published as a dated block when our team has run both intakes end to end. Pricing verified May 2026; both platforms adjust fees periodically — confirm current pricing before enrolling.

If you spot a pricing discrepancy or a factual error, email [email protected].